Clinilabs
, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have been selected to conduct a Phase I clinical research study of an investigational medication in patients with Chronic Obstructive Pulmonary Disease (COPD).
This is Clinilabs’ third clinical trial examining drug effects in patients with COPD. “As a specialty CRO, it is exciting to grow our franchise in respiratory disorders as we expand our expertise to an ever wider range of conditions” states Barbara Smallwood, Vice President of Business Development at Clinilabs.
Enrollment for this study is expected to begin in April 2011.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.